July 11 (Reuters) - Nyxoah SA NYXH.BR :
* NYXOAH RECEIVES FDA IDE APPROVAL TO INITIATE THE ACCCESS
STUDY
OF GENIO IN COMPLETE CONCENTRIC COLLAPSE PATIENTS
* FIRST PATIENT IS EXPECTED TO BE IMPLANTED DURING Q4 OF
2022,
IN-LINE WITH PRIOR GUIDANCE
* SEEING OUTSTANDING RESULTS IN CCC PATIENTS TREATED WITH
GENIO IN
EUROPE AND ARE EXCITED TO BEGIN ACCCESS STUDY - CEO
* TO EVALUATE USE OF GENIO SYSTEM TO TREAT ADULT PATIENTS
WITH
MODERATE-TO-SEVERE OSA AND COMPLETE CONCENTRIC COLLAPSE (CCC) OF
SOFT PALATE
* IN ACCCESS TRIAL, NYXOAH WILL IMPLANT UP TO 106 PATIENTS
WITH
CO-PRIMARY EFFICACY ENDPOINTS OF APNEA-HYPOPNEA INDEX (AHI)
RESPONDER RATE AND OXYGEN DESATURATION INDEX (ODI) RESPONDER
RATE
Source text for Eikon: ID:nGNX8CVW6m
Further company coverage: NYXH.BR
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48587696600;))